Pacira BioSciences 3Q 2026: Revenue $176.65M, EPS $0.7 — 10-Q Summary
Pacira BioSciences reported Q3 2026 revenue of $176.65M, down 2% YoY, but net income rose to $28.52M, up 425%. EXPAREL and ZILRETTA sales increased, while iovera° sales declined. Earnings benefited from gains related to contingent consideration and divestiture. Gross margin fell to 79% from 81%.
How this was made

The 30-second read
Why it matters
The earnings beat may attract short‑term buying pressure, but investors should watch for sustainability of profit drivers.
Market read
Earnings surprise provides a trading opportunity for PCRX and potentially influences peer biotech stocks.
What to watch
One-time contingent consideration and divestiture gains may not be repeatable.
Background
Pacira BioSciences filed its Q3 2026 10‑Q, highlighting modest revenue decline, strong profit growth, and progress on its PCRX‑201 pipeline.
Ticker impact
Q3 2026 results show revenue down 1.6% YoY but net income up 425% and EPS $0.7 versus $0.124 last year.
likely upward as market prices in the earnings beat and contingent gains.
Revenue decline is modest while net income and EPS dramatically exceed prior-year levels, indicating strong profitability.
Market effects
Pain management sector may see renewed interest due to strong earnings from a key player.
U.S. biotech investors could adjust positions in small-cap pharma stocks.
Limited to investors tracking U.S. biotech earnings.
Counterpoint
Revenue decline could signal slowing demand for core products, warranting caution.
Key entities
- companyPacira BioSciences
U.S. biotech firm reporting Q3 2026 results.

